Syndax Pharmaceuticals (SNDX) Current Deferred Revenue (2015 - 2021)

Syndax Pharmaceuticals' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $12.4 million for Q3 2021.

• In Q3 2021, Current Deferred Revenue rose 717.4% year-over-year to $12.4 million; the TTM figure through Sep 2021 stood at $12.4 million (up 717.4% YoY), while the FY2020 annual figure was $1.5 million, changed 0.0% from the prior year.
• Current Deferred Revenue for Q3 2021 stood at $12.4 million, up from $1.5 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $12.4 million in Q3 2021, with the low at $1.2 million in Q1 2017.
• The 5-year median for Current Deferred Revenue is $1.5 million (2018), against an average of $2.0 million.
• The sharpest annual moves came in 2018 and 2021: Current Deferred Revenue retreated 3.56% in 2018, then soared 717.4% in 2021.
• Syndax Pharmaceuticals' Current Deferred Revenue stood at $1.6 million in 2017, then fell by 3.56% to $1.5 million in 2018, then changed by 0.0% to $1.5 million in 2019, then changed by 0.0% to $1.5 million in 2020, then jumped by 717.4% to $12.4 million in 2021.
• Business Quant data shows SNDX's Current Deferred Revenue at $12.4 million in Q3 2021, $1.5 million in Q2 2021, and $1.5 million in Q1 2021.